Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh.

• Egile Nagusiak: Ridwanur Rahman (Egilea), Vishal Goyal (Egilea), Rashidul Haque (Egilea), Kazi Jamil (Egilea), Abul Faiz (Egilea), Rasheda Samad (Egilea), Sally Ellis (Egilea), Manica Balasegaram (Egilea), Margriet den Boer (Egilea), Suman Rijal (Egilea), Nathalie Strub-Wourgaft (Egilea), Fabiana Alves (Egilea), Jorge Alvar (Egilea), Bhawna Sharma (Egilea)
• Formatua: Liburua
• Argitaratua: Public Library of Science (PLoS), 2017-05-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

AmBisome therapy for VL has an excellent efficacy and safety profile and has been adopted as a first-line regimen in Bangladesh. Second-line treatment options are limited and should preferably be given in short course combinations in order to prevent the development of resistant strains. Combination...